In a randomized, single-blind, placebo-controlled study, Preeshila Behary et al. subcutaneously infused GLP-1, oxyntomodulin, and PYY for 4 weeks in 24 subjects with obesity and prediabetes/T2DM. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.